Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 7/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21209581 | 0.84 | L3MBTL1 (0.43) | HCAR2L3MBTL1LMNAHCAR3 | |
| SCHEMBL10130037 | 0.81 | HCAR2 (0.46) | HCAR2L3MBTL1LMNAHCAR3 | |
| SCHEMBL28788307 | 0.79 | L3MBTL1 (0.36) | L3MBTL1LMNA | |
| SCHEMBL1205898 | 0.78 | HCAR2 (0.49) | HCAR2L3MBTL1LMNAHCAR3 | |
| SCHEMBL18019765 | 0.76 | L3MBTL1 (0.35) | L3MBTL1LMNA | |
| SCHEMBL21217012 | 0.75 | HCAR2 (0.35) | HCAR2L3MBTL1LMNA | |
| SCHEMBL804646 | 0.73 | — | — | |
| SCHEMBL15831686 | 0.72 | HCAR2 (0.38) | HCAR2L3MBTL1HCAR3 | |
| SCHEMBL1628594 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL31648852 | 0.71 | HCAR2 (0.39) | HCAR2L3MBTL1LMNAHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022078305-A1 | HETEROCYCLIC DERIVATIVE AND MEDICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2022-04-21 | — | — | WO | disclosed |
| US-20210040083-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-02-11 | — | — | US | disclosed |
| US-10793563-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2020-10-06 | — | — | US | disclosed |
| WO-2019148132-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | WO | disclosed |
| US-20190233411-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233411-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | HCAR2 2854/4885L3MBTL1 2553/4885LMNA 3246/4885 |
| US-20210040083-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | HCAR2 2854/4885L3MBTL1 2553/4885LMNA 3246/4885 |
| US-10793563-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, GCGR | HCAR2 2854/4885L3MBTL1 2553/4885LMNA 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.